Clinical Scorecard: Impact of Gender-Affirming Hormone Treatment from Teen Years to Adulthood on Heart Function: A Cross-Sectional Analysis
At a Glance
Category
Detail
Condition
Cardiovascular effects of long-term gender-affirming hormone therapy (GAHT) initiated during adolescence
Key Mechanisms
Metabolic changes and hormonal influences on cardiac structure, function, and aortic elasticity associated with GAHT
Target Population
Transgender and gender diverse (TGD) individuals who started GAHT during adolescence
Care Setting
Specialized gender clinics and cardiovascular assessment centers
Key Highlights
Long-term GAHT (5–10 years) initiated during adolescence shows no apparent cardiac dysfunction or hypertrophy in young adult trans men and trans women.
Aortic diameters remain within normal ranges, but GAHT is associated with reduced aortic distensibility and strain, and increased aortic stiffness index.
In trans men, reduced aortic distensibility correlates independently with increased systolic blood pressure.
Guideline-Based Recommendations
Diagnosis
Perform echocardiographic evaluation including systolic and diastolic function, ventricular and aortic diameters, and aortic elasticity parameters in TGD individuals on long-term GAHT.
Management
Monitor cardiovascular risk factors such as hypertension, obesity, impaired glucose tolerance, dyslipidemia, smoking, and alcohol use in TGD patients receiving GAHT.
Consider blood pressure control strategies especially in trans men due to association with aortic stiffness.
Monitoring & Follow-up
Regular cardiovascular assessments including echocardiography to detect changes in aortic elasticity and cardiac function during and after GAHT.
Long-term follow-up to determine clinical significance of observed alterations in aortic elasticity.
Risks
Potential increased cardiovascular risk related to metabolic changes induced by GAHT and lifestyle factors.
Feminizing GAHT may increase thromboembolic risk due to pro-thrombotic effects of estrogens.
Masculinizing GAHT may raise hematocrit, blood pressure, and alter lipid profiles, influencing cardiovascular risk.
Patient & Prescribing Data
Young adult transgender men and women who initiated GAHT during adolescence and have been on treatment for 5–10 years.
GAHT does not significantly impair cardiac systolic or diastolic function or cause hypertrophy but affects aortic elasticity parameters; clinical implications require further study.
Clinical Best Practices
Initiate GAHT with careful cardiovascular risk assessment and counseling about potential metabolic and vascular effects.
Incorporate regular echocardiographic monitoring focusing on aortic elasticity and blood pressure management.
Address modifiable cardiovascular risk factors including lifestyle interventions to mitigate potential risks associated with GAHT.
Interpret cardiovascular findings in the context of affirmed gender and hormonal influences during adolescence.
